Dr Rachel Archer BSc, PhD (Sheffield) (formerly Jackson)
The University of Sheffield
Regent Court, 30 Regent Street
Sheffield, S1 4DA
Tel: (+44) (0)114 222 0793
Fax: (+44) (0)114 222 0749
I read for my first degree in genetics and microbiology before undertaking a PhD and postdoctoral research in molecular microbiology. I joined the Section of Public Health at ScHARR in August 2004 before moving to HEDS in August 2007.
My research interests include:
• systematic reviews of clinical effectiveness evidence
• systematic reviews of public health interventions
• development of methods for systematic reviewing and evidence synthesis
I am currently involved as a lecturer in the teaching of systematic review methods on undergraduate and postgraduate taught courses. I lead the delivery of a successful external short course in systematic review methods entitled The ScHARR systematic reviews course: Practical skills for undertaking reviews. I also play a strategic role in the delivery of teaching as a member of the HEDS Teaching Functional Working Group.
I am a member of the ScHARR Technology Assessment Group (ScHARR-TAG) and the ScHARR Public Health Collaborating Centre. I have undertaken leading and contributory roles in high quality research for the National Institute for Health and Clinical Excellence, the NHS and other funding organisations
I have previously worked on the following projects:
• NICE Single Technology Appraisal of the use of pegloticase in gout
• Assessment of the use of routine echocardiography in the management of stroke and transient ischaemic attack
• NICE Single Technology Appraisal of the use of golimumab in rheumatoid arthritis
• Assessment of evidence to inform Public Health Programme Guidance relating to the prevention and early identification of alcohol use disorders in adults and adolescents (funded by the National Institute for Health and Clinical Excellence) (lead systematic reviewer)
• Health Technology Assessment of the use of oseltamivir, amantadine and zanamivir for the prophylaxis of influenza (commissioned by the National Coordinating Centre for Health Technology Assessment (NCCHTA) on behalf of the National Institute for Health and Clinical Excellence) (lead systematic reviewer)
- Tappenden P, Ren S, Archer R, Harvey R, Martyn-St James M, Basarir H, Stevens J, Lobo A & Hoque S (2016) A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. PharmacoEconomics, 34(10), 1023-1038. View this article in WRRO
- Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, Young A & Wailoo A (2016) Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment, 20(35), 1-610. View this article in WRRO
- Essat M, Tappenden P, Ren S, Bessey A, Archer R, Wong R, Lobo A & Hoque S (2016) Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 34(3), 245-257. View this article in WRRO
- Archer R, Paisley S, Essat M, Preston L & Thornhill M (2015) ITERATIVE SIFTING IN THE SELECTION OF RESEARCH EVIDENCE: IMPLICATIONS FOR REVIEWS AND OTHER DECISION PROBLEMS. International Journal of Technology Assessment in Health Care, 31(1-2), 54-58. View this article in WRRO
- Holmes M, Rathbone J, Littlewood C, Rawdin A, Stevenson M, Stevens J, Archer R, Evans P & Wang J (2014) Routine echocardiography in the management of stroke and transient ischaemic attack: a systematic review and economic evaluation.. Health Technol Assess, 18(16), 1-176.
- Tosh J, Archer R, Davis S, Stevenson M & Stevens JW (2013) Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.. Pharmacoeconomics, 31(8), 653-661.
- Purshouse RC, Brennan A, Rafia R, Latimer NR, Archer RJ, Angus CR, Preston LR & Meier PS (2013) Modelling the cost-effectiveness of alcohol screening and brief interventions in primary care in England.. Alcohol Alcohol, 48(2), 180-188.
- Ara R, Blake L, Gray L, Hernández M, Crowther M, Dunkley A, Warren F, Jackson R, Rees A, Stevenson M, Abrams K, Cooper N, Davies M, Khunti K & Sutton A (2012) What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.. Health Technol Assess, 16(5), iii-195.
- Jackson RJ, Cooper KL, Tappenden P, Rees A, Simpson EL, Read RC & Nicholson KG (2011) Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review.. J Infect, 62(1), 14-25.
- Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R & Nicholson K (2009) Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.. Health Technol Assess, 13(11), iii-246.